<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082601</url>
  </required_header>
  <id_info>
    <org_study_id>09-137</org_study_id>
    <nct_id>NCT01082601</nct_id>
  </id_info>
  <brief_title>Catheter Ablation for Atrial Fibrillation and Heart Failure</brief_title>
  <official_title>Pulmonary Vein Isolation for Rhythm Control in Patients With Atrial Fibrillation and Left Ventricular Dysfunction: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare heart function, symptoms, exercise capacity and quality of life in patients with&#xD;
      Congestive Heart Failure (CHF) and Atrial Fibrillation (AF)before and after catheter&#xD;
      ablation.&#xD;
&#xD;
      Hypothesis: Restoration and maintenance of sinus rhythm by catheter ablation, without the use&#xD;
      of antiarrhythmic drugs, in AF and CHF improves heart failure status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no enrollment&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in LVESV by 15% or more from baseline at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remodeling as demonstrated by atrial &amp; ventricular dimensions on echocardiogram</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute hall walk test</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for HF</measure>
    <time_frame>one year</time_frame>
    <description>Composite hospitalization for HF,thromboembolic complications, major bleeding or all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Atrial fibrillation</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Optimal Medical therapy</arm_group_label>
    <description>Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Isolation (PVI)</intervention_name>
    <description>Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.</description>
    <arm_group_label>Optimal Medical therapy</arm_group_label>
    <other_name>Catheter Ablation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in either the out patient or in hospital environment at St.Luke's-Roosevelt&#xD;
        Hospital or The Valley Hospital, Ridgewood New Jersey, with systolic left ventricular&#xD;
        dysfunction and atrial fibrillation. Class I-III CHF based on symptoms(shortness of&#xD;
        breath,fatigue, peripheral edema and documented ejection fraction of less than 40%.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years to 80 years&#xD;
&#xD;
          -  Clinical diagnosis of CHF based on symptoms (Shortness of breath, fatigue, peripheral&#xD;
             edema)&#xD;
&#xD;
          -  Systolic left ventricular dysfunction with ejection fraction 40% or less&#xD;
&#xD;
          -  NYHA Class I, II or III heart failure&#xD;
&#xD;
          -  Paroxysmal AF(2 or more episodes in one month) that terminate within 7 days:or&#xD;
             persistent AF (more than 7 days or less than 7 days but terminated with pharmacologic&#xD;
             or electrical cardioversion).&#xD;
&#xD;
          -  Willing and able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ablation&#xD;
&#xD;
          -  Left atrial size greater than 60mm(parasternal view on transthoracic echocardiogram)&#xD;
&#xD;
          -  AF episodes triggered by another uniform arrhythmia(e.g.atrial flutter or atrial&#xD;
             tachycardia)&#xD;
&#xD;
          -  Active alcohol or drug abuse, which may be causative of AF&#xD;
&#xD;
          -  Severe valvular disease requiring surgical repair&#xD;
&#xD;
          -  Myocardial infarction within 6 months of enrollment&#xD;
&#xD;
          -  Abnormality that prevents catheter introduction&#xD;
&#xD;
          -  Coronary surgical revascularization or other cardiac surgery within 6 months of&#xD;
             enrollment&#xD;
&#xD;
          -  Patients in whom heart transplant expected with 6 months&#xD;
&#xD;
          -  AF deemed secondary to a transient or correctable cause (e.g.electrolyte imbalance&#xD;
             ,trauma,recent surgery,,infection, toxic ingestion or endocrinopathy&#xD;
&#xD;
          -  Pregnancy or women of child bearing potential &amp; not on reliable method of birth&#xD;
             control&#xD;
&#xD;
          -  Contraindication to Warfarin therapy or other bleeding diathesis&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
&#xD;
          -  Inaccessable to follow-up&#xD;
&#xD;
          -  Life expectancy of less than 24 months caused by reasons other than heart disease&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  Decompensated CHF within 48 Hours of enrollment&#xD;
&#xD;
          -  Second or third degree AV block or sinus pause greater than 3 seconds, resting heart&#xD;
             rate less 30 bpm without a permanent pacemaker&#xD;
&#xD;
          -  A history of drug induced Torsades de Pointes or congenital long QT syndrome&#xD;
&#xD;
          -  Currently responding to antiarrhythmic drug therapy&#xD;
&#xD;
          -  Uninterrupted AF for more than 12 months prior to randomization unless sinus rhythm&#xD;
             maintained for 24 hours or longer.&#xD;
&#xD;
          -  Unwilling or unable to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suneet Mittal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Luke's-Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Catheter Ablation</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

